The impact of E-cadherin expression on the prognosis of esophageal cancer: A meta-analysis

Diseases of the Esophagus

Volumn 27, Issue 1, 2014, Pages 79-86

  Xu, X L ^a   Ling, Z Q ^a   Chen, S Z ^b   Li, B ^a   Ji, W H ^a   Mao, W M ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Lishui Centre Hospital   (China)

Author keywords

CDH1; E cadherin; Esophageal neoplasm; Prognosis

Indexed keywords

UVOMORULIN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONFIDENCE INTERVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; META ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION;

CDH1; E-CADHERIN; ESOPHAGEAL NEOPLASM; PROGNOSIS;

ADENOCARCINOMA; CADHERINS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; PROGNOSIS;

EID: 84892477219     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12024     Document Type: Article

References (37)

1. Ferlay J, Shin H R, Bray F etal. GLOBOCAN 2008 V1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon: International Agency for Research on Cancer, 2010.
2. Berger B, Stahlberg K, Lemminger A etal. Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer. Oncology 2011; 81 (5-6): 387-394.
3. Come C, Magnino F, Bibeau F etal. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006; 12 (18): 5395-5402.
4. Pap Z, Pavai Z, Denes L etal. An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1. Pathol Oncol Res 2009; 15 (4): 579-587.
5. Hu X, Ruan Y, Cheng F etal. p130Cas, E-cadherin and beta-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol 2011; 18 (9): 630-637.
6. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. J Am Coll Surg 2001; 192 (6): 708-718.
7. Sasaki K, Natsugoe S, Ishigami S etal. Significance of Twist expression and its association with E-cadherin in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2009; 28: 158-167.
8. Shimada Y, Hashimoto Y, Kan T etal. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology 2004; 67 (1): 73-80.
9. Inada S, Koto T, Futami K etal. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 1999; 29 (6): 493-503.
10. Setoyama T, Natsugoe S, Okumura H etal. alpha-catenin is a significant prognostic factor than E-cadherin in esophageal squamous cell carcinoma. J Surg Oncol 2007; 95 (2): 148-155.
11. Uchikado Y, Natsugoe S, Okumura H etal. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11 (3): 1174-1180.
12. Takeno S, Noguchi T, Fumoto S etal. E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Am J Clin Pathol 2004; 122 (1): 78-84.
13. Shiozaki H, Doki Y, Yamana H etal. A multi-institutional study of immunohistochemical investigation for the roles of cyclin D1 and E-cadherin in superficial squamous cell carcinoma of the esophagus. J Surg Oncol 2002; 79 (3): 166-173.
14. Lin Y C, Wu M Y, Li D R etal. Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol 2004; 10 (22): 3235-3239.
15. Zhang G, Zhou X, Xue L etal. Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: immunohistochemical study. Pathol Int 2005; 55 (6): 310-317.
16. Chung Y, Lam A K, Luk J M etal. Altered E-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann Surg Oncol 2007; 14 (11): 3260-3267.
17. Bongiorno P F, al-Kasspooles M, Lee S W etal. E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett's oesophagus. Br J Cancer 1995; 71 (1): 166-172.
18. Chiba T, Kawachi H, Kawano T etal. Independent histological risk factors for lymph node metastasis of superficial esophageal squamous cell carcinoma; implication of claudin-5 immunohistochemistry for expanding the indications of endoscopic resection. Dis Esophagus 2010; 23 (5): 398-407.
19. Chung Y, Law S, Kwong D L etal. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 2011; 24 (1): 49-55.
20. Falkenback D, Nilbert M, Oberg S etal. Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis Esophagus 2008; 21 (2): 97-102.
21. Kadowaki T, Shiozaki H, Inoue M etal. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 1994; 54 (1): 291-296.
22. Krishnadath K K, Tilanus H W, van Blankenstein M etal. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997; 182 (3): 331-338.
23. Nakanishi Y, Ochiai A, Akimoto S etal. Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology 1997; 54 (2): 158-165.
24. Schauer M C, Stoecklein N H, Theisen J etal. The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett's adenocarcinoma is associated with favorable clinical staging. Eur J Med Res 2012; 17 (1): 10-18.
25. Shen W D, Ji Y, Liu P F etal. Correlation of E-cadherin and CD44v6 expression with clinical pathology in esophageal carcinoma. Mol Med Report 2012; 5 (3): 817-821.
26. Tamura S, Shiozaki H, Miyata M etal. Decreased E-cadherin expression is associated with haematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the oesophagus. Br J Surg 1996; 83 (11): 1608-1614.
27. Zhao X J, Li H, Chen H etal. Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol 2003; 9 (2): 225-232.
28. Natsugoe S, Uchikado Y, Okumura H etal. Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep 2007; 17 (3): 517-523.
29. Zhai J W, Yang X G, Yang F S etal. Expression and clinical significance of Ezrin and E-cadherin in esophageal squamous cell carcinoma. Chin J Cancer 2010; 29 (3): 317-320.
30. McShane L M, Altman D G, Sauerbrei W etal. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93 (4): 387-391.
31. Parmar M K, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17 (24): 2815-2834.
32. Tierney J F, Stewart L A, Ghersi D, Burdett S, Sydes M R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16-32.
33. Yusuf S, Peto R, Lewis J etal. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27 (5): 335-371.
34. Dong C, Wu Y, Yao J etal. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 2012; 122 (4): 1469-1486.
35. Sobin L H, Fleming I D. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80 (9): 1803-1804.
36. International Union Against Cancer. TNM Classification of Malignant Tumors, 4 edn. Berlin: Springer, 1990.
37. Japanese Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. Esophagus 2004; 1: 61-88.